Sino Historical Income Statement

688108 Stock

11.00 0.21 1.87%

Historical analysis of Sino Medical income statement accounts such as Selling General Administrative of 82.7 M, Total Revenue of 246.2 M or Gross Profit of 190.1 M can show how well Sino Medical Sciences performed in making a profits. Evaluating Sino Medical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sino Medical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Sino Medical Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sino Medical Sciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Sino Medical Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Sino Income Statement Analysis

Sino Medical Sciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sino Medical shareholders. The income statement also shows Sino investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Sino Medical Income Statement Chart

The current year's Interest Income is expected to grow to about 4 M, whereas Tax Provision is projected to grow to (23.2 M).

Tax Provision Selling General Administrative

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Sino Medical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sino Medical Sciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Sino Medical Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

The current year's Interest Income is expected to grow to about 4 M, whereas Tax Provision is projected to grow to (23.2 M).

	2021	2022	2023	2024 (projected)
Gross Profit	143.5M	121.7M	202.2M	190.1M
Total Revenue	194.4M	192.9M	343.3M	246.2M

Gross Profit Total Revenue

Sino Medical income statement Correlations

	Tax Provision	Net Interest Income	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Interest Income	Ebitda	Reconciled Depreciation	Minority Interest
Tax Provision		0.16	0.84	0.52	0.79	0.1	0.96	0.95	0.97	-0.91	-0.51	-0.82	0.97	0.95	0.97	-0.38	0.97	-0.93	-0.82
Net Interest Income	0.16		0.14	0.49	0.49	-0.52	0.15	0.19	0.21	0.17	0.06	0.24	0.18	0.19	0.23	0.78	0.22	0.1	-0.24
Selling General Administrative	0.84	0.14		0.62	0.79	0.36	0.86	0.84	0.86	-0.83	-0.3	-0.6	0.85	0.84	0.83	-0.37	0.83	-0.77	-0.61
Total Revenue	0.52	0.49	0.62		0.91	0.19	0.68	0.72	0.48	-0.43	0.39	0.04	0.68	0.72	0.43	0.26	0.44	-0.27	-0.37
Gross Profit	0.79	0.49	0.79	0.91		0.12	0.88	0.9	0.77	-0.66	-0.02	-0.31	0.88	0.9	0.73	0.09	0.74	-0.59	-0.59
Other Operating Expenses	0.1	-0.52	0.36	0.19	0.12		0.21	0.18	0.16	-0.37	0.16	-0.12	0.16	0.19	0.07	-0.61	0.1	-0.26	0.32
Operating Income	0.96	0.15	0.86	0.68	0.88	0.21		1.0	0.92	-0.93	-0.31	-0.69	1.0	1.0	0.9	-0.33	0.9	-0.88	-0.74
Net Income From Continuing Ops	0.95	0.19	0.84	0.72	0.9	0.18	1.0		0.9	-0.91	-0.26	-0.65	1.0	1.0	0.88	-0.27	0.88	-0.84	-0.74
Ebit	0.97	0.21	0.86	0.48	0.77	0.16	0.92	0.9		-0.88	-0.59	-0.82	0.93	0.9	0.99	-0.39	1.0	-0.93	-0.76
Research Development	-0.91	0.17	-0.83	-0.43	-0.66	-0.37	-0.93	-0.91	-0.88		0.43	0.83	-0.92	-0.91	-0.85	0.63	-0.85	0.94	0.67
Cost Of Revenue	-0.51	0.06	-0.3	0.39	-0.02	0.16	-0.31	-0.26	-0.59	0.43		0.82	-0.32	-0.25	-0.63	0.46	-0.62	0.67	0.44
Total Operating Expenses	-0.82	0.24	-0.6	0.04	-0.31	-0.12	-0.69	-0.65	-0.82	0.83	0.82		-0.69	-0.64	-0.84	0.72	-0.83	0.93	0.68
Income Before Tax	0.97	0.18	0.85	0.68	0.88	0.16	1.0	1.0	0.93	-0.92	-0.32	-0.69		1.0	0.91	-0.29	0.91	-0.87	-0.76
Net Income	0.95	0.19	0.84	0.72	0.9	0.19	1.0	1.0	0.9	-0.91	-0.25	-0.64	1.0		0.87	-0.27	0.88	-0.84	-0.72
Income Tax Expense	0.97	0.23	0.83	0.43	0.73	0.07	0.9	0.88	0.99	-0.85	-0.63	-0.84	0.91	0.87		-0.37	1.0	-0.93	-0.8
Interest Income	-0.38	0.78	-0.37	0.26	0.09	-0.61	-0.33	-0.27	-0.39	0.63	0.46	0.72	-0.29	-0.27	-0.37		-0.38	0.62	0.2
Ebitda	0.97	0.22	0.83	0.44	0.74	0.1	0.9	0.88	1.0	-0.85	-0.62	-0.83	0.91	0.88	1.0	-0.38		-0.93	-0.78
Reconciled Depreciation	-0.93	0.1	-0.77	-0.27	-0.59	-0.26	-0.88	-0.84	-0.93	0.94	0.67	0.93	-0.87	-0.84	-0.93	0.62	-0.93		0.66
Minority Interest	-0.82	-0.24	-0.61	-0.37	-0.59	0.32	-0.74	-0.74	-0.76	0.67	0.44	0.68	-0.76	-0.72	-0.8	0.2	-0.78	0.66

Click cells to compare fundamentals

Sino Medical Account Relationship Matchups

Sino Medical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	17.9M	6.3M	(31.8M)	(48.0M)	(24.5M)	(23.2M)
Net Interest Income	5.3M	6.6M	2.3M	257.2K	(1.3M)	(1.2M)
Interest Expense	4.8M	5.8M	2.2M	2.5M	3.7M	2.8M
Selling General Administrative	125.2M	96.2M	83.2M	83.4M	94.0M	82.7M
Total Revenue	435.9M	327.4M	194.4M	192.9M	343.3M	246.2M
Gross Profit	361.5M	261.6M	143.5M	121.7M	202.2M	190.1M
Other Operating Expenses	3.9M	1.2M	612.4K	5.8M	5.2M	3.0M
Operating Income	102.9M	13.7M	(156.1M)	(200.0M)	(57.8M)	(54.9M)
Net Income From Continuing Ops	90.0M	22.5M	(131.3M)	(173.3M)	(43.4M)	(41.2M)
Ebit	100.1M	11.9M	(156.1M)	(200.0M)	(180.0M)	(171.0M)
Research Development	89.6M	108.7M	148.9M	152.8M	114.1M	111.4M
Cost Of Revenue	74.4M	65.8M	50.9M	71.1M	141.0M	77.1M
Total Operating Expenses	333.0M	313.8M	350.4M	392.9M	401.1M	348.6M
Income Before Tax	108.0M	28.8M	(163.1M)	(221.3M)	(67.9M)	(64.5M)
Net Income Applicable To Common Shares	90.0M	22.5M	(130.8M)	(162.4M)	(146.1M)	(138.8M)
Net Income	90.0M	22.5M	(130.8M)	(162.4M)	(39.6M)	(37.6M)
Income Tax Expense	17.9M	6.3M	(31.8M)	(48.0M)	(43.2M)	(41.1M)
Interest Income	5.5M	6.7M	4.7M	3.0M	2.6M	4.0M
Ebitda	131.2M	61.4M	(95.5M)	(155.6M)	(140.1M)	(133.1M)
Reconciled Depreciation	28.1M	38.3M	65.4M	63.2M	62.8M	46.5M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

Other Information on Investing in Sino Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sino Historical Income Statement

About Sino Income Statement Analysis

Sino Medical Income Statement Chart

Tax Provision

Sino Medical income statement Correlations

Sino Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sino Medical income statement Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Sino Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income From Continuing Ops	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit

Reconciled Depreciation	- 0.93	Ebitda
Reconciled Depreciation	- 0.93	Income Tax Expense
Reconciled Depreciation	- 0.93	Ebit
Research Development	- 0.93	Operating Income
Reconciled Depreciation	- 0.93	Tax Provision
Income Before Tax	- 0.92	Research Development